Posts

(4) A Weed, a Patent Wall, and a Systemic Failure:

Image
A Weed, a Patent Wall, and a Systemic Failure: Why Cancer Foundations Must Step In for Dandelion Root Extract Research IPCSG Newsletter Informed Prostate Cancer Support Group Spring 2026 Edition  Advocacy & Policy Advocacy Brief Prepared for patient advocates, foundation program officers, and research administrators — fourth in the IPCSG dandelion root extract series The clinical trial gap for dandelion root extract is not a scientific verdict. It is a market failure produced by patent law, supplement industry perverse incentives, and chronic underfunding of non-patentable botanicals. Charitable foundations are uniquely positioned — and arguably uniquely obligated — to fill this void. Prepared by: IPCSG Editorial Team   Date: March 2026 Audience: Cancer Foundations, Advocates, Research Administrators   Type: Advocacy Brief Executive Summary Dandelion root extract (DRE) and its k...
Post a Comment
Read more

(2) Weed Not Just for Colon Cancer:

Image
Dandelion Root Extract, Prostate Cancer, and the Universality of Its Anti-Cancer Mechanisms IPCSG Newsletter Informed Prostate Cancer Support Group Spring 2026 Edition Research & Emerging Therapies   ← This article is a follow-on to our earlier piece, "The Dandelion That Fights Back," which covered dandelion root extract and colon cancer. This article expands the discussion to address whether the anti-cancer mechanisms are unique to colon cancer, and what the evidence says specifically about prostate cancer.  Our earlier article raised a question that IPCSG members immediately asked: are dandelion root's anti-cancer effects specific to colon cancer, or do they extend to prostate cancer and other tumors? The science provides a clear and encouraging answer — but with important nuances that matter to prostate cancer patients specifically. Prepared for: IPCSG Members & Cancer Community Date: March 20...
Post a Comment
Read more

(3) When Standard Options Are Exhausted:

Image
Could Dandelion Root Extract Have a Role in Prostate Cancer Failing ADT and Enzalutamide? IPCSG Newsletter Informed Prostate Cancer Support Group Spring 2026 Edition Editorial Analysis Editorial Analysis Third in a series on dandelion root extract and cancer — focusing on the specific clinical question of mCRPC failing standard hormonal therapy Clinical Relevance — mCRPC & Treatment-Refractory Disease This editorial directly addresses the clinical question raised by our members: given the preclinical evidence, is dandelion root extract a scientifically plausible option — as an adjunct or alternative — for men with prostate cancer that has progressed through ADT and newer agents like enzalutamide, short of radiotheranostics or chemotherapy? Prepared for: IPCSG Members — mCRPC Focus Date: March 2026 Type: Evidence-Based Editorial Analysis BLUF — Bottom Line Up Front The pr...
Post a Comment
Read more